Broker reiterates GSK 'buy' as court ruling lifts vaccine cloud

Shore Capital reiterated a Buy on GSK with a fair value target of 2,500p. Analyst Dr Sean Conroy says GSK (market cap ~£79bn) trades at 14x his 2026 earnings estimate and 12x his 2027 forecast, which he views as undemanding versus peers. The broker argues shares are too cheap given GSK's growth ambitions and that two of the market's main concerns are starting to fade.

Analysis

A re-rating of this large pharma would create immediate winners beyond the equity itself: CDMOs and CROs that absorb incremental clinical and commercial scale (Catalent, IQVIA) should see revenue visibility and margin leverage within 6–12 months as programme scale increases. Packaging, cold-chain logistics and emerging-market distributors will capture steady recurring revenue if product mix shifts toward vaccines and specialty care, while peers with slower pipeline conversion may see relative multiple compression.

Primary downside catalysts are operational and binary: negative late-stage readouts or regulatory delays would compress sentiment quickly and widen funding costs for pipeline programmes; these events can reverse gains within days to weeks. Macro and policy risks—drug-pricing headlines or EM currency shocks—operate on a 3–12 month cadence and would hit free-cash-flow conversion, making any valuation rerate fragile until multiple consecutive quarters of delivery are visible.

The consensus bullishness underestimates the need for visible capital-allocation discipline and repeatable margin expansion; investors are pricing in execution that still requires multiple sequential proof points (trial readouts, margin beats, buyback cadence). That makes a time-limited tactical approach superior to a buy-and-forget — you want exposure through catalyst windows while keeping convex hedges for binary clinical/regulatory outcomes.

Key Decisions for Investors

• Long GSK shares (ticker: GSK) on a 6–12 month horizon — accumulate on pullbacks >10% from current levels, target asymmetric upside (~30–40%) if multiple re-rating occurs; implement a 15% hard stop to limit single-stock risk.
• Call-spread: buy 9–12 month GSK call spread (buy near-the-money call / sell a higher strike) to capture re-rating with defined cost — target 2.5–3x payoff vs premium if catalyst sequence holds; max loss = premium paid, ideal if you prefer capped capital risk.
• Pair trade: long GSK / short SANOFI (ticker: SNY) 6–9 months — directional if GSK execution surprises positively; size so net sector delta is small (<25% notional of each leg) to isolate differential execution risk.
• Play the supply-chain capture: buy Catalent (CTLT) or IQVIA (IQV) on a 6–12 month view — expect 12–24% upside if programme scale accelerates; hedge with a small put position if late-stage volatility spikes to protect against program-specific backslides.